Search

Your search keyword '"Intlekofer, Andrew M"' showing total 231 results

Search Constraints

Start Over You searched for: Author "Intlekofer, Andrew M" Remove constraint Author: "Intlekofer, Andrew M" Search Limiters Available in Library Collection Remove constraint Search Limiters: Available in Library Collection
231 results on '"Intlekofer, Andrew M"'

Search Results

1. Limited stage high grade B-cell lymphoma with MYC, BCL2 and/or BCL6 rearrangements: BCL2 rearrangements drives the poor outcomes

2. Retrospective characterization of nodal marginal zone lymphoma

3. TP53 mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy

7. The Public Repository of Xenografts Enables Discovery and Randomized Phase II-like Trials in Mice

8. CD8+ T cell metabolic flexibility elicited by CD28-ARS2 axis-driven alternative splicing of PKM supports antitumor immunity

9. Coordinated alterations in RNA splicing and epigenetic regulation drive leukaemogenesis

10. Acquired resistance to IDH inhibition through trans or cis dimer-interface mutations

11. TP53mutations identify high-risk events for peripheral T-cell lymphoma treated with CHOP-based chemotherapy

12. Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting

13. JAK2/IDH-mutant-driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

15. Integrated DNA/RNA targeted genomic profiling of diffuse large B-cell lymphoma using a clinical assay

16. Immune Signature of Pembrolizumab Plus Gemcitabine, Vinorelbine, and Liposomal Doxorubicin As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

17. Molecular Profiling across Lymphoma Subtypes Using MSK-Impact Next Generation Sequencing

18. Characterization of a Large Cohort of Patients with Nodal Marginal Zone Lymphoma Shows Prolonged Survival, Time-to-Treatment, and Time-to-Transformation

19. Mitonuclear genotype remodels the metabolic and microenvironmental landscape of Hürthle cell carcinoma

24. Favorable Outcomes Among Patients with T-Cell/Histiocyte-Rich Large B-Cell Lymphoma Treated with Higher-Intensity Therapy in the Rituximab Era

25. Distinct Patterns of CD4+ and CD8+ T-Cell Clonal Expansion Enable Broad Clinical Responses to Pembrolizumab + GVD in Patients with Relapsed Hodgkin Lymphoma

26. Infectious Complications in Patients with Relapsed or Refractory (R/R) Non-Hodgkin's Lymphoma (NHL) Treated with the Anti-CD20xCD3 Bispecific Antibody (BsAb) Mosunetuzumab

27. Predicting Toxicities in Older Adults with Non-Hodgkin Lymphoma (NHL) Receiving Systemic Chemotherapy: A Prospective Geriatric Assessment (GA) Study

28. Clinical Characteristics and Outcomes of Limited Stage High Grade B-Cell Lymphoma with MYC/BCL2 and/or BCL6 Rearrangements: A Single Center Experience

29. Brentuximab Vedotin-Based Regimens for Older Patients with Newly Diagnosed Classical Hodgkin Lymphoma -Real World Experience

30. Impact of Early Histological Transformation on Survival in Patients with Follicular Lymphoma

31. A Phase 1b Multi-Center Study of the FLT3 Inhibitor Gilteritinib in Combination with the IDH1 Inhibitor Ivosidenib or the IDH2 Inhibitor Enasidenib for Patients with Relapsed or Refractory Acute Myeloid Leukemia Who Have Co-Occurring FLT3/IDH1 or FLT3/IDH2 Mutations

32. Responses and Outcomes after Second-Line Therapy in Transplant-Eligible Patients with DLBCL Relapse over 1 Year after First-Line Therapy

33. Real-Life Experience with Lenalidomide Plus Anti-CD20 Antibodies for the Treatment of Patients (pts) with Relapsed/Refractory (R/R) Indolent Non-Hodgkin Lymphoma (iNHL)

34. In vivo library screening identifies the metabolic enzyme aldolase A as a promoter of metastatic lung colonization

35. Phase II Study of Pembrolizumab Plus GVD As Second-Line Therapy for Relapsed or Refractory Classical Hodgkin Lymphoma

36. Nitrogen Trapping as a Therapeutic Strategy in Tumors with Mitochondrial Dysfunction

39. High Complete Response Rate Observed with Second-Line Chemo-Immunotherapy with Pembrolizumab and GVD (Gemcitabine, Vinorelbine, and Liposomal Doxorubicin) in Relapsed and Refractory Classical Hodgkin Lymphoma

40. Retrospective Analysis of Gemcitabine and Oxaliplatin (GemOx)-Based Treatment in Patients with Relapsed/Refractory Aggressive B-Cell Non-Hodgkin Lymphoma

41. JAK2/IDH-mutant–driven myeloproliferative neoplasm is sensitive to combined targeted inhibition

42. Pre-TCR signaling inactivates Notch1 transcription by antagonizing E2A

44. T-bet represses expression of PD-1 and sustains virus-specific CD8 T cell responses during chronic infection

45. Outcomes of Follicular Lymphoma Patients By Dynamic FLIPI at Diagnosis and Initial Treatment in the Post-Rituximab Era

46. Intervention Versus Observation: What Is the Appropriate Endpoint? Assessment of Endpoints in Patients with Advanced Stage Follicular Lymphoma Who Are Initially Observed

47. Benchmark of Progression Free Survival for Multiple Lines of Therapy in Follicular Lymphoma Treated in the Rituximab Era

48. Lymphoproliferation Caused by Fas Deficiency Is Dependent on the Transcription Factor Eomesodermin

49. Comprehensive Genomic Profiling (CGP) of Angioimmunoblastic T-Cell Lymphoma (AITL) to Prospectively Inform Diagnosis and Clinical Management

50. Distinctive Genomic Alterations in Testicular Diffuse Large B Cell Lymphoma

Catalog

Books, media, physical & digital resources